CAJ | 학술논문

目的：观察恩替卡韦治疗乙肝后肝硬化失代偿期的临床疗效。方法：对我院2010年2月～2012年2月收治的33例乙肝后肝硬化失代偿期患者采用口服恩替卡韦治疗，每天给药0．5mg，每天1次，观察为48周，比较患者治疗前后的生化、纤维化指标、HBV～DNA定量变化。结果：经过48周的治疗后，患者的ALT、AST较治疗前相比，均得到明显改善（P＜0．05），HBV～DNA水平较治疗前明显下降（P＜0．05）。结论：恩替卡韦能够快速抑制病毒复制，改善肝功能，且安全性较好，在一定程度上可逆转肝硬化。
목적：관찰은체잡위치료을간후간경화실대상기적림상료효。방법：대아원2010년2월～2012년2월수치적33례을간후간경화실대상기환자채용구복은체잡위치료，매천급약0．5mg，매천1차，관찰위48주，비교환자치료전후적생화、섬유화지표、HBV～DNA정량변화。결과：경과48주적치료후，환자적ALT、AST교치료전상비，균득도명현개선（P＜0．05），HBV～DNA수평교치료전명현하강（P＜0．05）。결론：은체잡위능구쾌속억제병독복제，개선간공능，차안전성교호，재일정정도상가역전간경화。
Objective:To investigate the therapeutic effect of entecavir on decompensated cirrhosis post hepatitis B infection .Meth-ods:Thirty-three cases with decompensated cirrhosis post hepatitis B infection admitted from February , 2010 to February, 2012 were treated orally with entecavir , 0.5mg once daily, for 48 weeks.The biochemical and fibrosis indexes, and quantitative changes in HBV-DNA were compared.Results:After 48 weeks of treatment, the levels of ALT and AST were improved compared with those before treatment (P<0.05), the levels of HBV-DNA significantly went down(P<0.05).Conclusion:It is proved that entecavir could rap-idly suppress hepatitis B virus copying and improve the liver function;it may reverse to some extent hepatitis B cirrhosis and it is safe for clinical usage.